overall survival benefit

JOSHA`s CRITICAL REVIEW OF „Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer”

A striking benefit in overall survival was observed, and a less striking benefit in progression-free survival. This is quite in contrast to other recent studies with checkpoint inhibitors demonstrating a…